No connection

Search Results

BMEZ vs QCRH

BMEZ
BlackRock Health Sciences Term Trust
BEARISH
Price
$15.54
Market Cap
$1.57B
Sector
Financial Services
AI Confidence
85%
QCRH
QCR Holdings, Inc.
BULLISH
Price
$92.77
Market Cap
$1.55B
Sector
Financial Services
AI Confidence
85%

Valuation

P/E Ratio
BMEZ
--
QCRH
12.1
Forward P/E
BMEZ
--
QCRH
10.8
P/B Ratio
BMEZ
--
QCRH
1.39
P/S Ratio
BMEZ
--
QCRH
4.42
EV/EBITDA
BMEZ
--
QCRH
--

Profitability

Gross Margin
BMEZ
0.0%
QCRH
0.0%
Operating Margin
BMEZ
0.0%
QCRH
41.3%
Profit Margin
BMEZ
0.0%
QCRH
36.19%
ROE
BMEZ
--
QCRH
12.06%
ROA
BMEZ
--
QCRH
1.37%

Growth

Revenue Growth
BMEZ
--
QCRH
17.1%
Earnings Growth
BMEZ
--
QCRH
19.4%

Financial Health

Debt/Equity
BMEZ
--
QCRH
--
Current Ratio
BMEZ
--
QCRH
--
Quick Ratio
BMEZ
--
QCRH
--

Dividends

Dividend Yield
BMEZ
8.49%
QCRH
0.43%
Payout Ratio
BMEZ
846.82%
QCRH
3.2%

AI Verdict

BMEZ BEARISH

The Advanced Deterministic Scorecard reveals severe financial health concerns with a Piotroski F-Score of just 1/9, indicating weak fundamental strength. The absence of an Altman Z-Score and all profitability metrics at 0.00% suggest opaque or non-existent earnings power and potential structural risks. Despite a high dividend yield of 8.49%, the unsustainable 846.82% payout ratio and bearish insider activity raise red flags. Combined with negative long-term price performance and lack of analyst coverage, the investment case lacks foundational support.

Strengths
High current dividend yield of 8.49% provides income appeal
Recent short-term price momentum: +16.6% over 6 months
Market cap of $1.57B indicates moderate size and potential liquidity
Risks
Piotroski F-Score of 1/9 signals severe financial weakness
Profit margins at 0.00% across all levels (gross, operating, net)
Extremely high payout ratio (846.82%) threatens dividend sustainability
QCRH BULLISH

QCRH exhibits a stable financial profile with a Piotroski F-Score of 4/9 and is currently undervalued, trading at $92.77, well below its Graham Number of $105.98 and Intrinsic Value of $220.96. The company demonstrates exceptional operational consistency, having beaten earnings estimates in nearly every quarter over the last 25 reporting periods. While technical trends and insider sentiment are currently bearish, the strong YoY revenue (17.10%) and earnings growth (19.40%) provide a powerful fundamental cushion. The valuation suggests a significant margin of safety for long-term investors.

Strengths
Exceptional earnings track record with consistent beats over 25 quarters
Strong growth profile with YoY earnings growth of 19.40%
Trading at a discount to both Graham Number and Intrinsic Value
Risks
Strongly bearish technical trend (10/100) indicating short-term price pressure
Low insider sentiment with net selling activity
Piotroski F-Score of 4/9 indicates only 'Stable' health rather than 'Strong'

Compare Another Pair

BMEZ vs QCRH: Head-to-Head Comparison

This page compares BlackRock Health Sciences Term Trust (BMEZ) and QCR Holdings, Inc. (QCRH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile